For example, a recent study (PRIMERA trial) including 44 patients revealed that androgen receptor (AR), prostate-specific antigen (PSA), and prostate-specific membrane antigen (PSMA) expression in circulating tumor cells (CTC)+ had no significant impact on PSA drop and survival in mCRPC patients [7]. The gene discussed is KLK3; the disease is neoplasm.